Otsuka Pharmaceutical Co., Ltd.
2-9 Kanda Tsukasa-cho
Chiyoda-ku
Tokyo
101-8535
Tel: 03-3292-0021
Website: http://www.otsuka.co.jp/
Email: wwwadmin@tky.otsuka.co.jp
185 articles with Otsuka Pharmaceutical Co., Ltd.
-
Immuneering Enters Collaboration with Astex Pharmaceuticals to Identify Novel Therapeutic Targets in Central Nervous System Disorder Using Disease Cancelling Technology
6/25/2020
Immuneering Corporation announced a collaboration between its neuroscience division, known as Alleo Labs, and Astex Pharmaceuticals, a wholly owned subsidiary of Otsuka Pharmaceutical Co. Ltd., to identify novel therapeutic targets for an undisclosed neurodegenerative disease.
-
Otsuka Announces Positive Top-line Results from Two Phase 3 Studies of Centanafadine for the Treatment of Attention-deficit Hyperactivity Disorder (ADHD) in Adult Patients
6/11/2020
Centanafadine, an investigational compound for the treatment of ADHD, demonstrated statistically significant improvements vs. placebo for primary and key secondary efficacy endpoints in both studies In the combined analysis of tolerability across the two studies, no adverse event was reported by more than 7 percent of patients An estimated 5 percent (11 million) adults in the U.S. are diagnosed with ADHD 1 TOKYO &
-
CORRECTING and REPLACING Sozosei Foundation Donates $439,000 to Support Those With Mental Health and Kidney Diseases
4/24/2020
Grants Distributed to Four Non-Profit Organizations Serving Patients, Healthcare Workers and Their Families Dealing with the Impact of COVID-19
-
Sozosei Foundation Donates $439,000 to Support Those With Mental Health and Kidney Diseases
4/23/2020
Grants Distributed to Four Non-Profit Organizations Serving Patients, Healthcare Workers and Their Families Dealing with the Impact of COVID-19
-
BioSpace Global Roundup, April 23
4/23/2020
Biopharma and life sciences groups from across the globe provide updates on their business and pipelines. -
Esperion and Otsuka Team Up for Cardiovascular Drug Development and Commercialization in Japan
4/21/2020
The collaboration for development and commercialization combines Esperion's knowledge in lipid management and Otsuka's extensive cardiovascular drug advancement and marketing in Japan. -
Nuvo Pharmaceuticals® Announces Approval of Takeda's Cabpirin Tablets in Japan, Triggering a US$2.0 Million Milestone Payment due in Q2 2020
3/31/2020
Takeda holds a non-exclusive license to Nuvo's Yosprala™ patent permitting it to market Capbirin in Japan
-
Teva Announces Positive Top-Line Results from AJOVY® (fremanezumab) Clinical Trials in Japan
2/3/2020
Teva Pharmaceutical Industries Ltd. announced positive results from two Phase 2/3 trials evaluating AJOVY® in patients in Japan. AJOVY is under development in Japan by Otsuka Pharmaceutical Co., Ltd. as part of a May 2017 exclusive license agreement for development and sales of AJOVY in Japan.
-
PhoreMost Enters Multi-Project Drug Discovery Collaboration With Otsuka Pharmaceutical
1/21/2020
PhoreMost’s next-generation phenotypic screening platform, SITESEEKER, to identify novel targets for Otsuka's therapeutics discovery programmes
-
PhoreMost and Otsuka Pharmaceutical Co. entered into a multi-project collaboration to seek out disease-relevant pathways that can be exploited for the development of gene therapies to treat different illnesses.
-
Merck Establishes Strategic Oncology Collaboration with Taiho and Astex
1/6/2020
Merck announced an exclusive worldwide research collaboration and license agreement with Taiho Pharmaceutical Co, Ltd., and Astex Pharmaceuticals, a wholly owned subsidiary of Otsuka Pharmaceutical Co., Ltd., focused on the development of small molecule inhibitors against several drug targets, including the KRAS oncogene, which are currently being investigated for the treatment of cancer.
-
50 million people worldwide live with symptomatic Alzheimer's, which has no cure. In honor of September 21st being World Alzheimer's Day, we evaluated the current therapies, drugs in the pipeline and disease outlook.
-
The fixed-dose combination was being evaluated in adults with intermediate and high-risk myelodysplastic syndrome and chronic myelomonocytic leukemia.
-
Astex and Otsuka Announce Results of the Phase 3 ASCERTAIN Study of the Novel Oral Cedazuridine/Decitabine Fixed-Dose Combination (ASTX727) in Patients with Myelodysplastic Syndromes (MDS) or Chronic Myelomonocytic Leukemia (CMML)
6/6/2019
Astex Pharmaceuticals, Inc. announce top-line results from the ASCERTAIN phase 3 study evaluating cedazuridine and decitabine fixed-dose combination (ASTX727) vs decitabine IV in adults with intermediate and high-risk MDS or CMML.
-
Verily Forms Strategic Alliances with Novartis, Otsuka, Pfizer and Sanofi to Transform Clinical Research
5/21/2019
Leading biopharmaceutical organizations join Project Baseline initiative to engage more patients and clinicians in research and speed evidence generation
-
Verily announced a strategic collaboration deal with Novartis, Otsuka, Pfizer, Sanofi and six major health systems.
-
National Kidney Foundation Honors Otsuka Pharmaceutical Company, Ltd. with 2019 Spring Clinical Meetings Corporate Innovator Award
5/2/2019
Otsuka Pharmaceutical Company, Ltd. has been selected to receive the 2019 Corporate Innovator Award from the National Kidney Foundation (NKF) at the 2019 Spring Clinical Meetings in Boston.
-
Denmark’s H. Lundbeck and Japan’s Otsuka Pharmaceutical announced that their brexpiprazole failed to meet its primary endpoint in two Phase III clinical trials to treat manic episodes in patients with bipolar I disorder.
-
Avanir Pharmaceuticals, Inc. Reaches Agreement in Principle with U.S. Department of Justice Regarding NUEDEXTA® (dextromethorphan HBr and quinidine sulfate) 20mg/10mg capsules
2/13/2019
Avanir Pharmaceuticals, Inc., an indirect subsidiary of Otsuka Pharmaceutical Co., Ltd., has reached an agreement in principle to resolve an investigation by the United States Department of Justice related to certain of Avanir's sales and marketing practices for its product NUEDEXTA® (dextromethorphan HBr and quinidine sulfate) 20mg/10mg capsules prior to 2017.
-
Data Demonstrate Safety and Efficacy of Brexpiprazole in Patients with Schizophrenia Experiencing Severe Psychotic Symptoms
10/26/2018
The Severity of Schizophrenia Symptoms Can Be a Significant Predictor of Poor Treatment Outcomes